Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
To strengthen the integrated human-centric preventive health screening ‘Phygital’ ecosystem in India
Subscribe To Our Newsletter & Stay Updated
